Peptide Therapeutics Market 2022-2028.rar

Peptide Therapeutics Market 2022-2028.rar

The global peptide therapeutics market is projected to grow at a significant CAGR of around 9.0% during the forecast period. Peptides are composed of short chains of amino acid monomers linked together via peptide bonds and occur naturally in the human body. Peptides are very specific in activity when compared to small molecules when used as a drug candidate. Generally having fewer side effects, peptides have become popular candidates for drug design. During the past decade, peptides have gained a wide range of applications in medicine and biotechnology, and therapeutic peptide research is also currently experiencing a renaissance for commercial reasons.

The primary factor that drives the growth of the market include the incidences of cancer along with other metabolic disorders across the globe. Additionally, the rising demand for cost-efficient and effective drugs, along with the rapid R&D activities in order to manufacture novel drugs for the treatment are also likely to contribute to the growth of the market during the forecast period.

However, limitations linked with the peptides, inadequate resources, and stringent regulations by the government are some of the factors that may challenge the growth of the market during the forecast period. Nevertheless, the presence of the key players continuously contributing to the growth of the market along with numerous government initiatives to successfully detect and treat cancer, which is providing opportunities for the growth of the market growth.

Segmental Outlook

The global peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into oral and parenteral. Based on the application, the market is segmented into cancer, gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others. Peptide therapeutics for cancer tend to contribute a considerable share to the market growth.

Cancer Segment to Contribute Considerably to the Market Growth

Amongst the application segment of the market, cancer is projected to be a major shareholding segment. The segmental growth of the market is attributed to the increased incidence of cancer across the globe and cancer is the leading cause of mortality in both developed as well as developing countries. Further, governments and private investments in R&D of cancer treatment, and reduction in the cost of treatment are some other factors that drive the segmental growth of the market during the forecast period. The increasing cases of cancer coupled with the increasing prescription of peptide therapeutics for the treatment of cancer gives a boost to the segmental growth of the market.

Regional Outlook

The global peptide therapeutics market is geographically segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is estimated to contribute significantly to the market during the forecast period. The growth of the region is backed by several factors including the presence of advanced healthcare infrastructure in the region. Further, the presence of the key players, increasing prevalence of cancer, and the adoption of technologically advanced products in countries such as the US and Canada further give a boost to the regional growth of the market.

According to the American Cancer Society in 2017, it was estimated that there were 600,920 cancer deaths in the US. The Asia Pacific is projected to exhibit the fastest growth in the global peptide therapeutics market over the forecast period. This is mainly attributed to the developing healthcare infrastructure along with the increasing medical tourism in the economies such as India.

Market Players Outlook

Some of the prominent players operating in the global peptide therapeutics market include Amgen Inc., Eli Lilly and Co., Pfizer, Inc., Bristol-Myer Squibb Co., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis International AG, Novo Nordisk A/S, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceuticals Industries Ltd., and others. These are the key companies adopting several organic and inorganic growth strategies such as product launches & developments, partnerships, agreements, and acquisitions to strengthen their product portfolios and maintain a competitive position in the global Peptide Therapeutics market. For instance, in September 2021, Merck & IRBM signed a new agreement in the peptide therapeutics area, continuing their long-standing history of collaboration that began in 2010.

The Report Covers

Market value data analysis of 2021 and forecast to 2028.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global peptide therapeutics market. Based on the availability of data, information related to products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.